Skip to main content
. 2021 Oct 15;12(10):1789–1808. doi: 10.4239/wjd.v12.i10.1789

Table 5.

Treatments and outcomes of diabetic survivors and non-survivors with coronavirus disease 2019


Total (n = 191)
Survivors (n = 165)
Non-survivors (n = 26)
P value
Treatments
Antiviral therapy 170 (89.0) 149 (90.3) 21 (80.8) 0.268
Antibiotic therapy 160 (83.8) 139 (84.2) 21 (80.8) 0.873
Systemic glucocorticoids 74 (38.7) 55 (33.3) 19 (73.1) < 0.001
Intravenous immunoglobulin 60 (31.4) 50 (30.3) 10 (38.5) 0.405
Renal replacement therapy 1 (0.5) 0 (0.0) 1 (3.8) 0.136
Insulin 88 (46.1) 75 (45.5) 13 (50.0) 0.666
Metformin 54 (28.3) 51 (30.9) 3 (11.5) 0.041
Sulfonylurea 37 (19.4) 36 (21.8) 1 (3.8) 0.031
DPP-4 inhibitor 11 (5.8) 10 (6.1) 1 (3.8) 1.000
Acarbose 77 (40.3) 75 (45.5) 2 (7.7) < 0.001
Thiazolidinedione 7 (3.7) 7 (4.2) 0 (0.0) 0.596
Oxygen support
Oxygenation 115 (60.2) 95 (57.6) 20 (76.9) 0.061
Mechanical ventilation 35 (18.3) 15 (9.1) 20 (76.9) < 0.001
Illness severity
Severe 63 (33.0) 37 (33.7) 26 (100) < 0.001
Complications
ARDS 21 (11.0) 5 (3.0) 16 (61.5) < 0.001
ACI 16 (8.4) 9 (5.5) 7 (26.9) 0.001
AKI 3 (1.6) 1 (0.6) 2 (7.7) 0.049
Secondary infection 22 (11.5) 10 (6.1) 12 (46.2) < 0.001
Shock 3 (1.6) 0 (0.0) 3 (11.5) 0.002
Hypoproteinemia < 30 g/L 28 (14.7) 22 (13.3) 6 (23.1) 0.314
Coagulopathy 36 (18.8) 26 (15.8) 10 (38.5) 0.013
Length of hospital stay, d 16.0 (10.0-25.0) 18.0 (11.5-26.0) 7.0 (3.0-11.0) < 0.001
ICU admission 22 (11.5) 11 (6.7) 11 (42.3) < 0.001
Duration from admission to ICU, d 4.00 ± 3.51 3.91 ± 3.11 4.09 ± 4.01 0.907

Data are expressed as n (%), mean ± SD or median (IQR). P values were calculated by t Test, Mann-Whitney U test, χ2 test, Fisher’s exact test as appropriate. Comparing groups of diabetic survivors and non-survivors. ACI: Acute cardiac injury; AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome.